<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)
NOVITRON INTERNATIONAL, INC.
----------------------------
(Name of Issuer)
COMMON STOCK, $.01 par value per share
--------------------------------------
(Title of Class of Securities)
670088103
---------
(CUSIP Number)
Third Security, LLC
The Governor Tyler
1902 Downey Street
Radford, Virginia 24141
Attention: Marcus E. Smith, Esq.
Telephone No.: 540-731-3344
---------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
Copy to:
John Owen Gwathmey, Esq.
Hunton & Williams
Riverfront Plaza, East Tower
951 East Byrd Street
Richmond, Virginia 23219
June 8, 2000
------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement
on Schedule 13G to report the acquisition which is the
subject of this Schedule 13D, and is filing this
schedule because of Rules 13d-1(e), (f) or (g),
check the following box [_].
Page 1 of 8 Pages
<PAGE>
-------------------------- ------------------------
CUSIP NO. 670088103 13D Page 2 of 8 Pages
-------------------------- ------------------------
------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Randal J. Kirk
------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
------------------------------------------------------------------------------
3 SEC USE ONLY
------------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF
------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
-----------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 401,133
-----------------------------------------------------------
OWNED BY 9 SOLE DISPOSITIVE POWER
EACH REPORTING
-----------------------------------------------------------
PERSON WITH 10 SHARED DISPOSITIVE POWER
401,133
------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
401,133
------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [_]
------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
27.8%
------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
------------------------------------------------------------------------------
<PAGE>
-------------------------- --------------------------
CUSIP NO. 670088103 13D Page 3 of 8 Pages
-------------------------- --------------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Clinical Chemistry Holdings, Inc. I.R.S. Identification No.: 52-2202556
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
(b) [_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) [_]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
-------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 398,133
-------------------------------------------------------------
OWNED BY 9 SOLE DISPOSITIVE POWER
EACH REPORTING
-------------------------------------------------------------
PERSON WITH 10 SHARED DISPOSITIVE POWER
398,133
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
398,133
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [_]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
27.6%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
<PAGE>
This Amendment No. 2 (the "Amendment") amends and supplements the Statement
on Schedule 13D, dated November 26, 1999 and filed on December 6, 1999, as
amended by Amendment No. 1 dated March 10, 2000 and filed on March 15, 2000 (the
"Original Schedule 13D"), relating to the Common Stock, par value $.01 per share
(the "Common Stock"), of Novitron International, Inc., a Delaware corporation
(the "Issuer"). Mr. Randal J. Kirk ("Mr. Kirk") and Clinical Chemistry
Holdings, Inc., a Delaware corporation that is controlled by Mr. Kirk ("CCH"
and, together with Mr. Kirk, the "Reporting Persons"), are filing this Amendment
to update the information in the Original Schedule 13D with respect to the
beneficial ownership of the Common Stock by the Reporting Persons.
Item 3. Source and Amount of Funds or Other Consideration.
--------------------------------------------------
Item 3 of the Original Schedule 13D is hereby amended and supplemented as
follows:
"On February 14, 2000, Mr. Kirk used approximately $1,530 of personal funds
to purchase 500 shares of Common Stock, and on February 15, 2000, Mr. Kirk sold
500 shares of Common Stock for approximately $1,470. During the period
commencing March 16, 2000 and ending May 2, 2000, CCH used approximately $13,460
of working capital to purchase 4,800 shares of Common Stock. During the period
commencing May 5, 2000 and ending May 16, 2000, Kirkfield, L.L.C., a Virginia
limited liability company that is controlled by Mr. Kirk ("Kirkfield"), used
approximately $9,105 of working capital to purchase 3,000 shares of Common
Stock."
Item 5. Interest in Securities of the Issuer.
-------------------------------------
Item 5(a) of the Original Schedule 13D is hereby amended to read in its
entirety as follows:
"The aggregate number and percentage of shares of Common Stock to which
this statement relates is 401,133 shares, representing 27.8% of the 1,441,925
shares outstanding as reported by the Issuer on February 8, 2000 in the Issuer's
Quarterly Report on Form 10-Q for the quarter ended December 31, 1999 (the most
recent available filing by the Issuer with the Securities and Exchange
Commission). CCH directly beneficially owns 398,133 of the shares to which this
statement relates, and Mr. Kirk could be deemed to have indirect beneficial
ownership of the shares directly beneficially owned by CCH. Kirkfield directly
beneficially owns 3,000 of the shares to which this statement relates, and Mr.
Kirk could be deemed to have indirect beneficial ownership of the shares
directly beneficially owned by Kirkfield."
Item 5(b) of the Original Schedule 13D is hereby amended to read in its
entirety as follows:
"Each of the Reporting Persons has, together with the other Reporting
Person, the shared power to vote or direct the vote and the shared power to
dispose or to direct the disposition of 398,133 shares of Common Stock reported
by it or him in Item 5(a) hereof. Mr. Kirk has, together with Kirkfield, the
shared power to vote or direct the vote and the shared power to
Page 4 of 8 Pages
<PAGE>
dispose or to direct the disposition of 3,000 shares of Common Stock reported by
him in Item 5(a) hereof."
Item 5(c) of the Original Schedule 13D is hereby amended and supplemented as
follows:
"The following table lists all transactions in shares of Common Stock by
the Reporting Persons that were effected on February 14, 2000, February 15, 2000
and during the period from March 10, 2000, the date on which Amendment No. 1 to
this statement was originally filed with the Securities and Exchange Commission,
through June 8, 2000. All such transactions were effected on The Nasdaq
SmallCap Market.
<TABLE>
<CAPTION>
Shares Purchased Average Price
Reporting Person Date (Sold) Per Share*
----------------------------------------------------------------------------
<S> <C> <C> <C>
Mr. Kirk 2/14/00 500 $3.00
Mr. Kirk 2/15/00 (500)** $3.00
CCH 3/16/00 100 $3.00
CCH 4/5/00 2,000 $2.50
CCH 4/13/00 600 $2.88
CCH 4/14/00 1,200 $3.00
CCH 5/2/00 900 $3.00
Mr. Kirk (Kirkfield) 5/5/00 1,200 $3.00
Mr. Kirk (Kirkfield) 5/11/00 500 $3.00
Mr. Kirk (Kirkfield) 5/16/00 1,300 $3.00
</TABLE>
* Price excludes commission.
** Reporting Persons have disgorged profits of $1,669.11 to the Issuer related
to this sale and the sale by CCH of 10,000 shares of Common Stock on March
13, 2000 in accordance with the requirements of Section 16(b) of the
Securities Exchange Act of 1934, as amended."
Item 7 Material to be Filed as Exhibits.
---------------------------------
The following document is being filed as an exhibit to this Amendment and
is incorporated herein by reference:
Exhibit 7. Joint Filing Agreement.
Page 5 of 8 Pages
<PAGE>
SIGNATURE
---------
After reasonable inquiry and to the best of their knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.
Date: June 9, 2000 /s/ Randal J. Kirk
------------------------------------
Randal J. Kirk
Date: June 9, 2000 CLINICAL CHEMISTRY HOLDINGS, INC.
By: /s/ Audrey Ho Ping Ting
--------------------------------
Audrey Ho Ping Ting
President and Chief Executive Officer
Page 6 of 8 Pages
<PAGE>
EXHIBIT INDEX
-------------
Exhibit Number Exhibit
-------------- -------
Exhibit 7. Joint Filing Agreement.
Page 7 of 8 Pages
